Skip to main content
B

BY-HEALTH CO.,LTD — Investor Relations & Filings

Ticker · 300146 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,160 across all filing types
Latest filing 2026-04-24 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 300146

About BY-HEALTH CO.,LTD

https://www.by-health.com

BY-HEALTH CO.,LTD. is a prominent enterprise specializing in the research, development, production, and distribution of dietary supplements. The company offers a comprehensive portfolio of vitamins, minerals, and herbal extracts designed to support various health needs, including immune function, bone health, and energy metabolism. Its brand architecture includes the flagship BY-HEALTH brand alongside specialized labels such as Life-Space for probiotics and GymMax for sports nutrition. The company emphasizes a "transparent factory" strategy, allowing for rigorous quality control and consumer trust through open manufacturing processes. BY-HEALTH focuses on scientific innovation and personalized nutrition, catering to a diverse demographic ranging from children to the elderly. By leveraging a multi-channel distribution network, the company maintains a significant presence in the health and wellness market, prioritizing product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于作废2024年限制性股票激励计划部分第二类限制性股票的公告
Share Issue/Capital Change Classification · 1% confidence The document is a formal announcement by the board of directors of a Chinese listed company (汤臣倍健股份有限公司) regarding the cancellation of part of the 2024 Restricted Stock Incentive Plan (415万 unvested shares). It details the history of the incentive plan, board and shareholder approvals, and the specific amounts of restricted shares being voided. This is not a quarterly or annual report, nor an earnings release or regulatory filing of a general nature; it specifically relates to a change in the company’s share capital structure through the voiding of previously granted shares under an equity incentive plan. Therefore, it falls under “Share Issue/Capital Change” (SHA).
2026-04-24 Chinese
2026年一季度报告
Regulatory Filings
2026-04-24 Chinese
关于调整2024年限制性股票激励计划授予价格的公告
Remuneration Information Classification · 1% confidence The document is an official corporate announcement detailing adjustments to the grant price under the company’s 2024 restricted stock incentive plan, a form of equity-based compensation for management/executives. It is not an annual or quarterly report, earnings release, share buyback, or dividend notice. Rather, it addresses changes to a share‐based executive incentive/remuneration scheme, fitting the “Remuneration Information” category (DEF 14A) for disclosure of executive compensation plans.
2026-04-24 Chinese
关于与专业投资机构共同投资暨关联交易的公告
Regulatory Filings Classification · 1% confidence The document is a formal announcement (“公告”) by 汤臣倍健股份有限公司 regarding a joint investment with a professional investment institution, structured as a related-party transaction. It includes board approval details, transaction terms, risk disclosures, and compliance with Shenzhen Stock Exchange rules. It is not a financial report (10-K, IR, ER, etc.), not an investor presentation (IP), not a dividend or voting result notice, nor a share issuance/buyback. It is a mandatory regulatory disclosure of a specific transaction, best classified under Regulatory Filings (RNS).
2026-04-24 Chinese
国浩律师（广州）事务所关于汤臣倍健股份有限公司2024年限制性股票激励计划作废部分限制性股票的法律意见
Regulatory Filings Classification · 1% confidence The document is a standalone legal opinion letter issued by Grandall Law Firm (Guangzhou) regarding the cancellation of certain unvested restricted shares under the company’s 2024 incentive plan. It is not a financial report (annual or interim), not an earnings release, not management or board change notice, not a proxy or voting result, nor a financing or M&A announcement. It does not fit any specialized category (e.g., share issue, dividend, insider deal). Therefore, it falls under the fallback “Regulatory Filings” category (RNS).
2026-04-24 Chinese
国浩律师（广州）事务所关于汤臣倍健股份有限公司调整2024年限制性股票激励计划授予价格的法律意见
Regulatory Filings Classification · 1% confidence The document is a formal legal opinion letter from Grandall Law Firm regarding the legal aspects of adjusting the grant price under the company's 2024 restricted stock incentive plan. It does not present financial results, management changes, financing activities, or earnings, nor is it a proxy or remuneration disclosure in the sense of an executive compensation schedule. It is not a lawsuit update but rather a legal opinion supporting a corporate governance action. No specific category exists for “legal opinion letters,” so this falls under the fallback “Regulatory Filings (RNS)” category.
2026-04-24 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.